The introduction of hybrid technology — positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography (SPECT)/CT -— has revolutionized the imaging world. This technology allows the combination of the exquisite anatomic details provided, for example, by CT, with the important and much needed functional, physiologic or metabolic information provided by molecular imaging. 

New endovascular grafting techniques to repair tissue following abdominal aortic aneurysm rupture are generating growing enthusiasm among vascular surgeons, and a number of those new treatment options were presented at the 39th VEITHsymposium held in New York City Nov. 14 to 18.

Stryker announced the global commercial launch of the new Trevo ProVue Retriever. The Trevo ProVue Retriever is the first clot removal device fully visible during the procedure for precise positioning within the clot and optimized clot retrieval in patients experiencing acute ischemic stroke. Previous technology only provided visibility to the edges of the device.

Nov. 15, 2012 (GLOBE NEWSWIRE) -- Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, will unveil a national mobile and internet platform for consumers and demonstrate how enterprise imaging solutions support achieving Meaningful Use objectives at the Radiological Society of North America (RSNA) in booth #4845.

The U.S. Food and Drug Administration (FDA) has granted market clearance for the Avinger Inc. Ocelot optical coherenace tomography (OCT) catheter to help cross chronic total occlusions (CTOs) in patients with peripheral artery disease (PAD).

The U.S. Court of Appeals for the Federal Circuit affirmed an April 2010 federal jury decision that Medtronic CoreValve LLC is willfully infringing  Edwards Lifesciences' U.S. Andersen transcatheter heart valve patent. The Appeals Court also ordered the trial court to reconsider Edwards' request for a permanent injunction that would prohibit the manufacture and sale of the CoreValve System in the United States.

The U.S. Patent and Trademark Office has awarded Biomedical Systems U.S. Patent Number 8301236 for its TruVue Wireless Ambulatory ECG Monitoring System.  Biomedical Systems developed TruVue for the diagnosis and management of atrial fibrillation, considered the leading preventable cause of stroke affecting nearly three million Americans at a cost of $26 billion each year. The Centers for Disease Control and Prevention estimates the number of people impacted by atrial fibrillation to grow five times the current rate by 2050.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now